CAN
LENZ

Cetera Advisor Networks’s LENZ Therapeutics LENZ Stock Holding History

Cetera Advisor Networks’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,057
Closed -$179K – 2194
2021
Q4 		$179K Buy
2,057
+428
+26% +$35.5K ﹤0.01% 1899
2021
Q3 		$187K Buy
+1,629
New +$241K ﹤0.01% 1816

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cetera Advisor Networks's LENZ Position: Q1 2022 in Review

Cetera Advisor Networks sold out of LENZ Therapeutics (LENZ) in Q1 2022, closing a stake of 2,057 shares — an estimated $179K sold.

Cetera Advisor Networks first reported a position in LENZ in Q3 2021 and held it in 2 quarters. The position peaked at $187K in Q3 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q1 2022.

  • Cetera Advisor Networks reported no remaining LENZ Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cetera Advisor Networks sold 2,057 LENZ Therapeutics shares in Q1 2022, an estimated $179K.
  • Cetera Advisor Networks first reported a position in LENZ Therapeutics in Q3 2021 and held it in 2 quarters.
  • Cetera Advisor Networks's LENZ Therapeutics position peaked at $187K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2022.

Based on Cetera Advisor Networks's 13F filing for Q1 2022, filed 12 May 2022.